[Federal Register Volume 72, Number 165 (Monday, August 27, 2007)]
[Notices]
[Pages 49012-49013]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 07-4157]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of 
the Recombinant DNA Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Recombinant DNA Advisory Committee.
    Date: September 17-18, 2007.
    Time: September 17, 2007, 8 a.m. to 12 p.m.
    Agenda: The Recombinant DNA Advisory Committee will review and 
discuss elected human gene transfer protocols as well as related 
data management activities. There will also be a discussion about 
new clinical safety information.
    Place: National Institutes of Health, Natcher Building, 45 
Center Drive, Auditorium, Bethesda, MD 20892.
    Time: September 17, 2007, 12:30 p.m. to 6 p.m.
    Agenda: Continued.
    Place: National Institutes of Health, Building 31, Floor 5C, 31 
Center Drive, Conference Room 6, Bethesda, MD 20892.
    Time: September 18, 207, 8 a.m. to 12 p.m.
    Agenda: Continued.
    Place: National Institutes of Health, Building 31, Floor 6C, 31 
Center Drive, Conference Room 6, Bethesda, MD 20892.
    Contact Person: Laurie Lewallen, Advisory Committee Coordinator, 
Office of Biotechnology Activities, National Institutes of Health, 
6705 Rockledge Drive, Room 750, Bethesda, MD 20892-7985, 301-496-
9838, [email protected].

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.
    Information is also available on the Institute's/Center's home 
page: http://www4.od.nih.gov/oba/, where an agenda and any 
additional information for the meeting will be posted when 
available.
    OMB's ``Mandatory Information Requirements for Federal 
Assistance Program Announcements'' (45 FR 39592, June 11, 1980) 
requires a statement concerning the official government programs 
contained in the Catalog of Federal Domestic Assistance. Normally 
NIH lists in its announcements the number and title of affected 
individual programs for the guidance of the public. Because the 
guidance in this notice covers virtually every NIH and Federal 
research program in which DNA recombinant molecule techniques could 
be used, it has been determined not be cost effective or in the 
public interest to attempt to list these programs. Such a list would 
likely require several additional pages. In addition, NIH could not 
be certain that every Federal program would be included as many 
Federal agencies, as well as private organizations, both national 
and international, have elected to follow the NIH Guidelines. In 
lieu of the individual program listing, NIH invites readers to 
direct questions to the information address above about whether 
individual programs listed in the Catalog of Federal Domestic 
Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research General; 93.39, Academic 
Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency 
Syndrome Research Loan Repayment Program; 93.187, Undergraduate 
Scholarship Program for Individuals from

[[Page 49013]]

Disadvantaged Backgrounds, National Institutes of Health, HHS)

    Dated: August 15, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-4157 Filed 8-24-07; 8:45 am]
BILLING CODE 4140-01-M